Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis

Dimple Chakravarty¹, Sudipa Saha Roy¹, Challa Ram Babu¹, Rajasekhar Dandamudi¹, Tyler J. Curiel², Pablo Vivas-Mejia³, Gabriel Lopez-Berestein⁴,⁵,⁶,⁷, Anil K. Sood⁵,⁶,⁷ and Ratna K. Vadlamudi¹

¹The Department of Obstetrics and Gynecology, ²the Department of Med/Hematology & Med Oncology and CTRC at The UT Health Science Center, San Antonio, Texas; ³The Department of Biochemistry and Cancer Center, University of Puerto Rico, Medical Science Campus, San Juan, PR 00935. ⁴Departments of Experimental Therapeutics, ⁵Gynecologic Oncology, ⁶Cancer Biology, ⁷Center for RNA interference and non-coding RNA, University of Texas MD Anderson Cancer Center, Houston, Texas.

This study was supported by NIH-CA0095681, W81XWH-06-1-0398, CTRC P30CA54174, U54CA151668, CA083639 and OCRF grants.

Address correspondence to:

Ratna K. Vadlamudi, PhD
Division of Reproductive Research
Department of Obstetrics and Gynecology
The University of Texas Health Science Center at San Antonio
7703 Floyd Curl Drive, Mail Code 7836
San Antonio, TX 78229-3900
Tel: (210) 567-4930
Fax: (210) 567-4958
E-mail: vadlamudi@uthscsa.edu

Running title: Significance of PELP1 in ovarian carcinoma

Key words: Nuclear receptor, PELP1, coactivator, oncogene, ovarian cancer, genomic signaling, metastasis
Statement of Translational Relevance

Ovarian carcinoma is the leading cause of death due to gynecological malignancy. In this study, we investigated whether PELP1 signaling plays a role in ovarian epithelial cancer cell migration/metastasis and determined the therapeutic potential of PELP1-siRNA in vivo using a nanoliposomal formulation of PELP1-siRNA-DOPC. Our results demonstrate that PELP1 plays a critical role in ovarian cancer cell migration and modulates expression of several genes involved in metastasis. We found that PELP1-siRNA-DOPC can effectively reduce PELP1 expression and significantly reduce the tumor growth in ovarian xenografts. The results suggest that PELP1 signaling axis is a potential druggable target and liposomal PELP1-siRNA-DOPC could be used as a novel drug to prevent or treat ovarian metastasis.
Abstract

**Purpose:** Ovarian cancer remains a major threat to women’s health, partly due to difficulty in early diagnosis and development of metastases. A critical need exists to identify novel targets that curb the progression and metastasis of ovarian cancer. In this study, we examined whether the nuclear receptor coregulator PELP1 contributes to progression and metastatic potential of ovarian cancer cells and determined whether blocking of the PELP1 signaling axis had a therapeutic effect.

**Experimental Design:** Ovarian cancer cells stably expressing PELP1-shRNA were established. Fluorescent microscopy, Boyden chamber, invasion assays, wound healing and zymography assays were performed to examine the role of PELP1 in metastasis. Expression analysis of the model cells using was conducted to identify PELP1 target genes. Therapeutic potential of PELP1-siRNA *in vivo* was determined using a nanoliposomal formulation of PELP1-siRNA-DOPC administered systemically in a xenograft model.

**Results:** PELP1 knockdown caused cytoskeletal defects and significantly affected the migratory potential of ovarian cancer cells. Microarray analysis revealed that PELP1 affected the expression of selective genes involved in metastasis including Myc, MTA1, MMP2 and MMP9. Zymography analysis confirmed that PELP1 knockdown caused a decrease in the activation of MMP2 and MMP9. Compared to control siRNA-DOPC treated mice, animals injected with PELP1-siRNA-DOPC had 54% fewer metastatic tumor nodules, exhibited a 51% reduction in tumor growth and an 84% reduction in ascites volume.

**Conclusion:** The results suggest that PELP1 signaling axis is a potential druggable target and liposomal PELP1-siRNA-DOPC could be used as a novel drug to prevent or treat ovarian metastasis.
Introduction

Ovarian carcinoma continues to be the leading cause of death due to gynecological malignancy in the United States because it is usually diagnosed in the advanced stage of the disease [1, 2]. The standard treatment for epithelial ovarian cancer remains surgical debulking and chemotherapy with a platinum and taxane agent. Although many patients with disseminated tumors respond initially to standard combinations of surgical and cytotoxic therapy, nearly 90% of them develop recurrence [3]. A widely recognized behavior of ovarian cancer is its ability to migrate and seed the peritoneal cavity with nests of tumor cells and the formation of ascites [4]. The transition from early- to advanced-stage ovarian cancer is a critical determinant of survival; yet, little is known about the molecules that contribute to progression and metastasis of ovarian tumors.

The biological functions of hormones are mediated by nuclear receptors (NRs) and several recent studies demonstrated the presence of NRs in ~70% of ovarian epithelial tumors. In the past decade it has become increasingly clear that the sole existence of NRs is not sufficient for optimal NR function; several coregulatory proteins are also required [5, 6]. Many coregulatory proteins are present at rate-limiting levels, are shared by many NRs, and have the potential to control the expression of various subsets of genes to regulate cell processes coordinately such as proliferation, and metastasis [7]. With the enormous potential of coregulators as master regulators, their deregulation is likely to provide the cancer cells an advantage in proliferation, survival, and metastasis [8, 9]. As a consequence there is a critical
need to identify and understand the physiological role of master coregulators that promote initiation and progression of ovarian cancer and metastasis.

Proline-, glutamic acid-, leucine-rich protein-1 (PELP1) [10] is an NR coregulator that interacts with many NRs including estrogen receptor [11]. PELP1 is predominantly localized in the nuclear compartment, interacts with histones and histone-modifying enzymes, and thus plays a role in chromatin remodeling for ligand-bound NRs [11]. PELP1 promotes cell proliferation by sensitizing cells to G1>S progression via its interactions with the pRb pathway [12]. PELP1 is also unique because it plays important roles in both the genomic [13] and non-genomic actions of the NRs [11]. PELP1 is a recently identified proto-oncogene [14]. Its expression is deregulated in hormonal-dependent cancers including those of breast, endometrial and ovaries [15-17].

In this study, we investigated whether PELP1 signaling plays a role in ovarian epithelial cancer cell migration and metastasis by silencing PELP1 expression in ovarian cancer cells and in orthotopic models of ovarian cancer. Our findings revealed that PELP1 modulates metastasis of ovarian cancer cells by regulating expression of a number of genes involved in metastasis. Silencing endogenous PELP1 expression via nanoliposomal siRNA targeted to PELP1 (siRNA-PELP1-DOPC) \textit{in vivo} significantly reduced tumor growth, number of tumor nodules in the peritoneal cavity and ascites volume. Our results suggest that PELP1 plays a critical role in ovarian cancer progression to metastasis and thus represents a novel therapeutic target for curbing ovarian metastasis.

\textbf{Materials and Methods}
Cell cultures and reagents. OVCAR3, and ES2 cells were purchased from the American-Type Culture Collection (ATCC) and maintained in RPMI 1640 supplemented with 20% fetal bovine serum (FBS; Hyclone Laboratories Ltd, Logan, UT). The derivation of the ovarian cancer cell line SKOV3ip1 has been described [18]. These cells were cultured in RPMI-1640 medium supplemented with 15% fetal bovine serum and 0.1% gentamicin sulfate (Gemini Bioproducts, Calabasas, CA). Non-tumorigenic SV40 Tag-immortalized ovarian surface epithelial derived cells (IOSE-80) were earlier described [19] and cultured in medium 199:MCDB 105 (1:1; Sigma-Aldrich Corp., St Louis, MO) containing 15% FBS. Antibodies against vinculin were purchased from Sigma Chemical Co (St. Louis, MO). The PELP1 antibody was purchased from Bethyl laboratories (Montgomery, TX) and antibodies for MMP2, H3K9Ac and H3K9me2 were purchased from Millipore (Billerica, MA).

Generation of PELP1-shRNA model cells. Ovarian cancer cells stably expressing PELP1-shRNA were generated using the FuGENE-6 transfection reagent (Roche, Indianapolis, IN) and were selected with G418 selection (500 μg/mL). Pooled clones were used for all the studies. For IOSE cells, electroporation (Nucleofection) was used to transfect PELP1 plasmids as previously described [20]. The PELP1-specific Sure Silencing shRNA plasmids, catalog # KH19454N and control shRNA vector were purchased from SABiosciences (Frederick, MD). The targeted sequences were PELP1-shRNA1: GGACCAAGGTGTATGCGATAT; PELP1-shRNA2: ATGCTGCTGTCCTC AGAAGAT. The PELP1-shRNA design was based on the GenBank accession number NM_014389. For transient knockdown of PELP1 was achieved using On-TargetPlusSMARTpool siRNA (L-004463-00-0050) purchased from Thermoscientific and by using oligofectamine transfection (Invitrogen, Carlsbad, CA).
**Microarray studies:** The human Tumor Metastasis Microarray (Oligo GE array) was from SABiosciences and contains 113 genes known to be involved in metastasis. Total RNA isolated from OVCAR3 and OVCAR3-PELP1shRNA cells was used for screening. Probe preparation and hybridization was performed per manufacturer’s instructions. Target genes whose expression were differentially regulated (at least 3 fold difference) by PELP1 underexpression were selected and validated using real-time PCR in OVCAR3 and SKOV3ip1 cells. Validated real time PCR primers were used for validation of PELP1 regulated genes and all primers were purchased from RealTimePrimers.com.

**Cell migration, invasion and MMP reporter gene assays.** The cell migration was determined using 8 μmol/L pore calorimetric cell migration assay kit (Chemicon, Billerica, MA) using the manufacturer’s protocol. For the cell migration assay, 10^5 cells/300 μL of serum-free medium were seeded onto the upper chamber, and 0.75 mL of complete growth medium containing 10% fetal bovine serum was added to each well in the lower chamber [21]. Invasion assays were performed using BD Biocat growth factor reduced Matrigel invasion chamber (BD Biosciences, San Diego, CA) as per manufacturer’s protocol. The PGL3-MMP9-Luc promoter plasmid that contains 1305 bp of proximal promoter region of human MMP9 was received from Dr. Xu [22]. The PGL3-MMP2-Luc promoter plasmid that contains 1659 bp of proximal promoter region of human MMP2 was received from Dr. Benveniste [23]. Reporter gene assays were performed by transient transfection using FuGENE6 method (Roche Indianapolis, IN) as described [24]. Each transfection was carried out in 6-well plates in triplicate and normalized with β-gal activity and the total protein concentration.
**Gelatin Zymography:** The culture supernatant of model cells expressing control or PELP1-shRNA was used to determine the enzymatic activity of MMP2 and MMP9 by using SDS-PAGE gelatin zymography as described [25] using Novex Zymogram Gels (Invitrogen, Carlsbad, CA). Recombinant MMP2 and MMP9 were purchased from R&D systems was used as positive controls.

**ChIP assays.** ChIP assay was done using antibodies specific for PELP1, H3K9Ac, H3K9me2 or isotype rabbit IgG control in SKOV3ip1 cells as described [24]. DNA recovered from ChIP or input controls was subjected to real-time quantitative PCR using primers spanning various regions of MMP9 promoter as described [22]. Sequences of MMP promoter primers used: A-F:cttcagagccaggcagttct; A-R:agcctctcgtttcatcctca; B-F:taattgggcctggagatttg; B-R:agcctctcgtttcatcctca; C-F: taagacatttgcccgaggtc; C-R:cctctttttcccctctgac; D-F:ggaggtgtgtgaagcccttt; D-R:agggcagaggtctgactg. The promoter occupancy was calculated based on the ratio of ChIP/input control.

**Immunofluorescence studies.** Confocal microscopy was performed as previously described [21]. For these studies, cells were grown on glass coverslips and fixed in 3.7% paraformaldehyde for 15 min at room temperature. The fixed cells were then permeabilized with 0.2% TritonX-100 in PBS for 15 mins followed by blocking with 5% normal goat serum (Sigma) in PBS for 1 h. The DNA dye 4',6-diamidino-2-phenylindole (Molecular Probes) was used to co-stain the DNA (blue). The F-actin status was analyzed by phalloidin staining (FITC conjugated from Molecular Probes) for 1 h at room temperature.

**Preparation of liposomal siRNA.** For in vivo delivery, PELP1-siRNA was incorporated into 1,2-dioleoyl-sn-glycerol-3-phosphatidylcholine (DOPC) nanoliposomes as described previously [26, 27]. Briefly, siRNA and DOPC were mixed in excess tertiary butanol at a ratio...
of 1:10 (w/w) respectively. Subsequently, Tween 20 was added to the mixture at the ratio of 1:19 (Tween 20:siRNA/DOPC). The mixture was vortexed and frozen in an acetone/dry ice bath and lyophilized. For in vivo administration, the mixture was hydrated with 0.9% saline to a concentration of 15 µg/mL, and 200 to 250 µL of the mixture was used for each injection. siRNA for preparation of liposomes were purchased from Sigma. The targeted sequences used were: PELP1, 5’-ccacagagccugacucua3’; Control, 5’uucuccgaacgugacagu3”.

**Nude mice studies.** For in vivo injections, the SKOV3ip1 cells [28] were trypsinized, washed twice with PBS and reconstituted in serum-free HBSS (Invitrogen) at a concentration of 5 x 10^6 cells/mL, which were then injected intraperitoneally (i.p.) in 5–6-week-old female athymic nude mice. To examine the effects of PELP1 siRNA therapy on tumor growth, treatment was initiated 1 wk after i.p. injection of tumor cells. Mice were randomly assigned into two groups (n = 8 mice per group): (a) control siRNA-DOPC (150 µg/kg i.p. twice weekly), and (b) PELP1 siRNA-DOPC (150 µg/kg i.p. twice weekly). The mice were monitored daily for adverse affects and the treatment was continued for 27 days. On day 27, mice were euthanized and the total weight, tumor weight, number of metastatic tumor nodules, and volume of ascitic fluid were recorded. Tissue samples were snap frozen for lysate preparation or fixed in formalin for paraffin embedding.

**Immunohistochemistry.** Immunohistochemical analysis was performed as described [20]. Briefly, tumor sections were incubated overnight with the primary antibodies (PELP1 (1:500), MMP9 (1:50). The sections were then washed three times with 0.05% Tween in PBS for 10 min, incubated with secondary antibody for 1 h, washed three times with 0.05% Tween in PBS for 10 min, developed with 3,3V-diaminobenzidine-H2O2, and counterstained with Mayer’s hematoxylin. PCNA (1:100) from Vector Lab was used in conjunction with proper controls,
visualized by DAB substrate and counterstained with hematoxylin (Vector Lab, Inc. CA). Proliferative index was calculated as percentage of PCNA-positive cells in 10 randomly selected microscopic fields at 100X per slide. TUNEL analysis was done using the In situ Cell Death Detection Kit (Roche, Indianapolis, IN) as per the manufacturer’s protocol and ten randomly selected microscopic fields in each group were used to calculate the relative ratio of TUNEL-positive cells. MMP9 expression tumors was quantified as the number of positive cells \( \times \) 100/total number of cells counted under \( \times 100 \) magnification in 10 randomly selected areas in each tumor sample.

**Statistical analysis.** Statistical differences among groups were analyzed with either t-test or ANOVA as appropriate using SPSS software.

**Results**

**PELP1-shRNA clones exhibit defects in cytoskeletal reorganization.** Recently, we established OVCAR3 model cells that stably express PELP1 shRNA [20]. These cells had less growth potential and distinct flat morphology compared to the morphology of OVCAR3 parental or OVCAR3-vector cells. To further explore this phenotypic observation, we generated two additional ovarian cancer cells (SKOV3ip1 and ES2) that stably express PELP1 shRNA. These cells had a 70-80% decrease in the expression of PELP1 (Fig. 1A). Interestingly, SKOV3ip1 and ES2 cells expressing PELP1 shRNA also exhibited flat morphology (data not shown). We therefore examined whether the lack of PELP1 expression contributes to cytoskeletal defects in ovarian cancer cells. OVCAR3 (Fig. 1B) and SKOV3ip1 (Fig. 1C) control cells as well as PELP1 shRNA expressing cells were serum starved and treated with or without EGF for 10 min, and filamentous actin status was analyzed by phallloidin staining. Serum starved control cells
exhibited low F-actin structures with peripheral cortical actin, and EGF stimulation promoted increased formation of ruffles and fillopodia (Fig. 1B, 1C). Interestingly in PELP1 knockdown cells, EGF treatment did not promote formation of fillopodia or ruffles. However, PELP1-shRNA cells had increased accumulation of stress fibers, which is also an indication of less motile cells (Fig. 1B, C). Similar defects in actin reorganization were also seen in ES2 cells expressing PELP1-shRNA were stimulated with either EGF or estrogen (Fig. 1D). Collectively, these results suggest that PELP1 signaling plays a role in cytoskeletal reorganization and could be required for optimal actin reorganization in ovarian epithelial cells.

*PELP1 downregulation affects expression of selective genes involved in metastasis.*

PELP1 plays a critical role in NR genomic functions via chromatin remodeling and by modulating histone code at the NR target promoters [29]. Since PELP1 knockdown cells had defects in cell shape and cytoskeletal reorganization, we examined whether the lack of expression of PELP1 affects the expression of genes involved in cell migration/metastasis by using a focused microarray approach. We used the Human Tumor Metastasis Microarray, which contains 113 genes known to be involved in metastasis including genes involved in cell adhesion, ECM components, cell cycle, cell growth and proliferation, apoptosis, transcription factors and regulators, and other genes related to tumor metastasis. Total RNA isolated from OVCAR3 and OVCAR3-PELP1shRNA cells was used for the array analysis and the results from this screen suggested that PELP1 downregulation substantially reduced the expression of a number of genes, including MMP2, MMP9, MTA1, Myc and SMAD2 compared to their expression in control cells (Fig. 2A). We validated the changes seen in the array study by measuring gene expression of the top five genes that had significant reduction by performing real-time qPCR on the OVCAR3 PELP1 shRNA cells or control shRNA cells (Fig. 2B). The
changes in the expression of these genes were also independently confirmed in SKOV3ip1 cells expressing PELP1 siRNA that target a different site in PELP1 as compared to PELP1-shRNA targeting site (Fig. 2C). These results suggest that PELP1 has potential to modulate expression of genes involved in the cell migration/metastasis.

**PELP1 expression is needed for optimal activation of MMPs.** Since PELP1 downregulation altered expression of MMPs and because MMPs are known to promote cancer progression by enhancing cell growth, migration, invasion, and metastasis of ovarian cancer cells [30, 31], we examined whether the reduction in the expression seen in PELP1 shRNA clones translates to lower MMPs activity. The activity of MMP2 and MMP9 was determined in SKOV3ip1 and ES2 cells expressing control or PELP1-siRNA by using gelatin zymography. MMP2 and MMP9 activities were lower in PELP1 knockdown cells than in control cells (Fig. 3A). To examine the mechanism by which PELP1 regulate MMP2 and 9 expression, we have performed promoter-Luc assays using previously published MMP2 and MMP9 reporter genes [22, 23]. In both SKOV3ip1 and ES2 model cells, knock down of PELP1 significantly reduced the MMP2 and MMP9 reporter gene activation (Fig. 3B). We examined further to check whether PELP1 mediated regulation of MMPs is due to PELP1 recruitment to the promoter regions of MMPs using a ChIP based assay. Initially, we have used four different primers that recognize various regulatory regions reported to activate MMP9. ChIP results showed that PELP1 is uniquely recruited to the proximal promoter region of MMP9 (Fig. 3C) and no recruitment in distal regions was observed. Emerging data implicates that PELP1 associates with acetylases (p300, CBP) and demethylases (KDM1) and participates in epigenetic modifications that are required for optimal transcriptional activation [11]. We therefore examined whether PELP1 down regulation affects epigenetic modifications at the MMP9 proximal promoter. ChIP analysis
revealed that PELP1 knock down enhances repressive mark H3K9me2 and decreases activation mark H3K9ac (Fig. 3D). These results suggest that PELP1-mediated genomic actions may play a role in PELP1 modulation of the expression and function of MMPs.

**PELP1 is involved in ovarian epithelial cell migration and invasion.** To examine further whether overexpression of PELP1 in IOSE cells increases their’s migratory potential, we studied IOSE cells over-expressing PELP1 in a Boyden chamber assay. Overexpression of PELP1 substantially enhanced the migratory potential of IOSE cells (Fig. 4A). On the other hand, compared to control cells, PELP1 knockdown in SKOV3ip1 cells resulted in significantly reduced migration in Boyden chamber assays (Fig. 4B, left panel). Similarly, ES2-PELP1 knockdown cells also revealed significantly less migration (Fig. 4C, right panel). PELP1 knock down also significantly reduced the invasion potential of both SKOVip1 and ES2 cells (Fig. 4C). Collectively these results suggest that PELP1 has potential to modulate the expression of the genes that are involved in migratory and invasion potential of ovarian epithelial cells.

**PELP1-siRNA reduce ovarian cancer cell growth in vitro and tumor progression in vivo.** We next examined whether PELP1 down regulation affects proliferation of ovarian cancer cells in vitro using a Cell Titer-Glo assay. PELP1 siRNA transfected SKOV3ip1 and ES2 showed substantially reduced cellular proliferation compared to control siRNA transfected cells (Fig. 5A). We then examined whether systemically administered PELP1siRNA in a nanoliposomal formulation (PELP1-siRNA-DOPC) reduced tumor growth by using an ovarian cancer xenograft model. Nude mice were injected with SKOV3ip1 ovarian cancer cells (1 x 10⁶ cells i.p). One week later, mice (n=8/group) were randomly assigned to receive therapy with either 150 μg/kg control siRNA-DOPC or PELP1-siRNA-DOPC every three days based our
previous dose-response experiments for effective down regulation of genes in vivo [26]. After 27 days, mice were euthanized. IHC examination of the tumors revealed that PELP1-siRNA-DOPC treated tumors had low expression of PELP1 (Fig. 5B). No toxicities were observed in behavioral changes including eating habits and mobility in animals treated with liposomes and mouse weights were not significantly different between control and PELP1-siRNA treatment groups (Fig. 5C). Compared to control siRNA-DOPC treated mice, nude mice treated with PELP1-siRNA-DOPC had a significant reduction in metastatic tumor nodules (54%, \( p < 0.001 \)), a reduction in tumor growth (51%, \( p < 0.001 \)) and reduction in ascites volume (84%, \( p < 0.001 \), Fig. 5C). PCNA staining of the tumor sections revealed a reduction in the proliferation in the PELP1-siRNA-DOPC treated tumors and 60% of cells in control siRNA treated tumors were PCNA positive, while only 20% of cells were PCNA positive in PELP1 siRNA treated tumors (Fig. 5D). Tunnel assay results showed increased apoptosis in PELP1 siRNA treated cells compared to control siRNA. PELP1-siRNA-DOPC treated tumors also had lower expression of MMP9 than the control tumors (Fig. 5D). Collectively, these results suggest that PELP1 down regulation decreases tumor cell proliferation and increases apoptosis and that PELP1-siRNA-DOPC can be used therapeutically for reducing ovarian cancer growth in vivo.

**Discussion**

Among the gynecologic malignancies reported for Western countries, ovarian cancer has the highest mortality rate and is the most common [32]. Despite modest improvements in response rates, overall survival rates remain disappointing for patients with advanced ovarian cancer [33]. A widely recognized behavior of ovarian cancer is its ability to migrate and seed the peritoneal cavity with nests of tumor cells and the formation of ascites [4]. We found that (a)
PELP1 plays a role in ovarian tumor cell cytoskeletal reorganization, (b) PELP1 downregulation affects expression of genes involved in metastasis, (c) PELP1 is recruited to promoters of MMPs and is required for optimal activation of MMPs, (d) PELP1 overexpression in normal IOSE cells promote cell migration (e) PELP1 knockdown substantially affected ovarian cancer ability to migrate in Boyden chamber and invasion assays, and (f) down regulation of PELP1 in vivo by PELP1-siRNA-DOPC substantially reduced ovarian tumor progression in xenograft models. Collectively, these results suggest that PELP1 signaling confers growth and metastatic advantages to ovarian epithelial cells.

Eventhough individual proto-oncogenes may play a role in oncogenesis, master regulators that control activities of multiple oncogenes and NRs can provide a growth advantage to cancer cells. Emerging findings suggest that NR-coregulator proteins have potential to be differentially expressed in malignant tumors, and that their functions may be altered, leading to tumor progression [7]. A few recent studies examined the status of NR coregulators in ovarian tumors and found deregulation of a few coregulators, including AIB1, SRA, and ARA70 [34-36]. Further, AIB1 KO mice studies demonstrated that normal expression of the coregulator AIB1 is required for initiation of tumorigenesis by carcinogens and oncogenes [37, 38], suggesting coregulators can play a vital role in tumor initiation and/or progression. PELP1 is a unique NR coregulator that interacts with a number of NRs [11]. Its expression is deregulated in ovarian cancers [20]. Using a metastasis array, we have identified a close linkage between PELP1 expression in ovarian cells with the activation of many genes that are implicated in metastasis. Our results suggest that PELP1 is a central NR coregulator that plays a critical role in ovarian cancer progression and metastasis.
A number of oncogenes that allow cells to grow independently from the host signals have been identified in ovarian cancer. The proto-oncogene c-Src is of interest in ovarian tumors as overexpression of Src has been demonstrated in 93% of advanced-stage ovarian tumors [39] and inhibition of cSrc in preclinical models can inhibit ovarian tumor growth [40]. Disruptions of the p16-CDK4/cyclin D1-pRb pathway (RB pathway) also plays an important role in the development of ovarian cancers [41]. PELP1 couples NR signaling to cell cycle progression via the pRb pathway [12] and PELP1 is a recently identified substrate of CDKs [24]. Emerging evidence suggests that PELP1 is a proto-oncogene [14] and collaborates with activation of other oncogenes including Src [11]. Growth factor and hormonal signals promote PELP1 interactions with cytosolic kinases leading to activation of MAPK and AKT pathways. Our results that PELP1 knock down substantially affect the growth of ovarian cancer cells in vitro and in vivo also supports a role of PELP1 in providing growth advantage to ovarian cancer cells. PELP1 mediated crosstalk with cytosolic kinases and cell cycle proteins may provide growth advantage in PELP1 deregulated ovarian cancer cells.

Accumulating evidence suggest that PELP1 function as a large scaffolding protein and modulates gene transcription via protein-protein interactions with histone-modifying acetylases/deacetylases [42], and methyltransferases/demethylases. A recent study identified PELP1 as a component of the MLL1 methyltransferase complex [43]. We found that PELP1 functions as a modifier of dimethyl-modification of histones [29]. Our results from the current study demonstrated that PELP1 signaling affects the ovarian cancer cell cytoskeleton and their migration. Gene array and expression analyses found that PELP1 has the potential to activate the transcription of genes involved in metastasis. ChIP studies revealed that PELP1 is recruited to the proximal promoter region of MMM9 and PELP1 knock down enhances repressive mark
H3K9me2 and decreases activation mark H3K9ac at the proximal promoter. These results suggest that PELP1-mediated genomic functions play a role in expression of genes involved in metastasis.

Currently, no known drugs inhibit PELP1 functions. Therefore, in this study we developed PELP1-siRNA nanoliposomes to examine the in vivo therapeutic potential of inhibiting PELP1. We examined the ability of systemically administered PELP1-siRNA to silence PELP1 gene expression in vivo using a xenograft model. The advantage of DOPC nanoliposomes is that they have no electrical charge. This neutrality provides an advantage over positively or negatively charged liposomes when it comes to binding with and penetrating cells (28). Another advantage of DOPC nanoliposomes is their small size (65 -125 nm) that enables their transport through blood vessels. Several recently published studies validated in vivo delivery of siRNA using DOPC-based liposomes and proved that this method is therapeutically efficacious [26, 44, 45]. We found that PELP1-siRNA-DOPC can effectively reduce PELP1 expression and significantly reduced the tumor growth in ovarian xenografts. Peritoneal surfaces are the most common site of ovarian metastases. The reduction in the number of tumor nodules found in the PELP1-siRNA-DOPC treated nude mice indicate that PELP1-siRNA-DOPC has potential to block ovarian metastasis. These results suggest that PELP1-siRNA-DOPC can be used as a novel drug for therapeutic targeting of PELP1 in ovarian cancer.

In summary, our results demonstrate that the NR coregulator PELP1 plays a critical role in ovarian cancer cell migration and modulates expression of several genes involved in metastasis. Even through earlier studies found that PELP1 plays a role in the proliferation of hormone-driven tumors, this study demonstrated that it also has the potential to promote metastasis of ovarian epithelial cells. Further, our study results provide the first in vivo evidence
that PELP1-siRNA-DOPC can be used as a line of therapy in ovarian cancer metastasis. Since multiple signaling pathways are involved in optimal generation of biological outcomes, targeting master regulators such as PELP1 is clinically relevant and will have better therapeutic effect.

Reference List


Figure Legends

Fig. 1. PELP1 knockdown promotes defects in actin reorganization of ovarian epithelial cells. A, OVCAR3, SKOV3ip1, ES2 cells untransfected, and or stably expressing negative control (NC) shRNA vector or PELP1-shRNA were lysed and the expression of PELP1 was analyzed by Western blotting. OVCAR3 (B), SKOV3ip1 (C) cells untransfected, and or stably expressing vector or PELP1-shRNA were treated with EGF (100 ng/μl) for 10 min. The status of F-actin was analyzed by confocal microscopy. D, ES2 cells untransfected, and or stably expressing vector or PELP1-shRNA were treated with EGF (100 ng/μl) or E2 (10^-9M) for 10 min. The status of F-actin was analyzed by confocal microscopy.

Fig. 2. PELP1 knockdown affects expression of selective genes involved in metastasis. A, RNA isolated from OVCAR3-shRNA negative control and OVCAR3-PELP1-shRNA expressing cells were hybridized to the human tumor metastasis Oligo GE Array. Changes in the gene expression were analyzed using SABioscience software with actin as a control for normalization. Representative genes downregulated upon PELP1 depletion are shown. B, Real-time qPCR validation of the changes in gene expression in OVCAR3 cells stably expressing negative control shRNA or PELP1-shRNA. C, SKOV3ip1 cells were transiently transfected with control or PELP1 specific siRNA and the expression of indicated genes was analyzed real-time qPCR.

Fig. 3. PELP1 regulates the expression and activities of MMPs. A, Gelatin zymography analysis of activity of MMP2 and MMP9 in SKOV3ip1 and ES2 cells that were transfected with control siRNA or PELP1-siRNA. B, SKOV3ip1 and ES2 cells transfected with MMP9-Luc and MMP2-
Luc vectors, treated with control siRNA or PELP1-siRNA and the reporter gene activity was measured after 72 hours. C, ChIP assay was done using the DNA isolated from SKOV3ip1 cells and by using antibodies specific for PELP1 or isotype rabbit IgG control. DNA recovered from ChIP or input controls was subjected to real-time quantitative PCR using four primers (A, B, C, D) that span the MMP9 promoter region. D, SKOV3ip1 cells were transfected with control or PELP1-siRNA and ChIP assay was done using antibodies specific for H3K9Ac or H3K9me2. DNA recovered from ChIP or input controls was subjected to real-time quantitative PCR using primers that detect proximal MMP9 promoter region. The promoter occupancy was calculated based on the ratio of ChIP/input control. **, \( p \leq 0.001 \), \( t \) test.

**Fig. 4.** PELP1 knockdown affects the migration and invasion of ovarian cancer cells. A, Migratory potential of IOSE cells overexpressing control vector or PELP1 expression vector was analyzed by using a Boyden chamber assay. B, Cell migration potential of SKOV3ip1 and ES2 cells transfected with control of PELP1 siRNA was analyzed by using a Boyden chamber assay. Photomicrographs of migrated cells in various treatments are shown. C, Cell invasion potential of SKOV3ip1 and ES2 cells transfected with control of PELP1 siRNA was analyzed using Matrigel invasion chamber assays. Photomicrographs of invaded cells in various treatments are shown. Columns, mean from three independent experiments; bars, SEM. **, \( p < 0.001 \), \( t \) test.

**Fig. 5.** PELP1-siRNA reduce ovarian cancer cell growth *in vitro* and tumor progression *in vivo*. A, Cell proliferation capacity of SKOV3ip1 and ES2 cells were analyzed after treating the cells with control or PELP1 siRNA using Cell Titer-Glo assay. B, IHC analysis of PELP1 expression in tumors treated with control or PELP1siRNA liposomes. C, Number of tumor nodules, mean
tumor weight, and ascites volume in control-siRNA-DOPC or PELP1-siRNA-DOPC treated groups (n=8/group). Column, mean tumor weights; bars, SEM. *, \( p \leq 0.05 \); **, \( p \leq 0.001 \), \( t \) test.

D, PCNA expression as a marker of proliferation, TUNEL staining as a marker of apoptosis and MMP9 expression was analyzed by immunohistochemistry (IHC) in tumors (n=8/group) treated with control or PELP1-siRNA-DOPC; Quantitation was done as described in methods section, bars, SEM. **, \( p< 0.001 \)
Figure 2

A

![Bar graph for PELP1-shRNA expression comparison with Control-shRNA](image1)

B

![Bar graph for PELP1-si expression comparison with Control-si](image2)

C

![Bar graph for PELP1 expression comparison with Control](image3)
Figure 3
Figure 4

A

 Relative migration (OD 560 nM)

Con vec
PELP1

Vector
PELP1-WT

IOSE

B

 Relative migration (OD 560 nM)

Un trans
Con si
PELP1 si

SKOV3ip1

Un trans
Con si
PELP1 si

ES2

Un trans
Con si
PELP1 si

C

invaded cell count

Un trans
Con si
PELP1 si

SKOV3ip

Un trans
Con si
PELP1 si

ES2

Un trans
Con si
PELP1 si

**

** NS

Downloaded from clincancerres.aacrjournals.org on September 12, 2017. © 2011 American Association for Cancer Research.
Figure 5

A) Relative luminescence of SKOV3ip1 and ES2 cells with con- and PELP1-siRNA.

B) Images showing the effect of PELP1-siRNA on cell morphology.

C) Graphs showing the effects of PELP1-siRNA on number of nodules, tumor weight, ascites volume, body weight, and MMP-9.

D) Images showing the effect of PELP1-siRNA on PCNA and TUNEL staining.
Clinical Cancer Research

Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis

Dimple Chakravarty, Sudipa Saha Roy, Rambabu Challa, et al.

Clin Cancer Res  Published OnlineFirst March 18, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-10-2718

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.